Last updated: February 27, 2026
What is the Drug NDC 27241-0041?
The National Drug Code (NDC) 27241-0041 corresponds to a biosimilar or biological product. Based on current data, this NDC is associated with Adalimumab, a monoclonal antibody used for treating autoimmune conditions, such as rheumatoid arthritis, Crohn’s disease, and psoriasis. It is marketed in biosimilar formulations.
Market Landscape
Market Size and Revenue
The global adalimumab market was valued at approximately $32 billion in 2022, driven predominantly by the U.S. and Western European markets. Biosimilars, including the product associated with NDC 27241-0041, account for around 15-20% of total adalimumab sales in North America. Uptake has increased following patent expirations in late 2018 and 2019.
Key Competitors
| Product |
Manufacturer |
Market Share (Est.) |
Launched |
Key Features |
| Humira |
AbbVie |
80% |
2003 |
Original biologic |
| Amjevita |
Amgen |
10% |
2017 |
First biosimilar in U.S. |
| Cyltezo |
Boehringer Ingelheim |
5% |
2018 |
FDA-approved biosimilar |
| Hadlima |
Samsung Bioepis |
3% |
2019 |
Cost-effective biosimilar |
| Imraldi |
Biosimilar manufacturer |
<2% |
2018 |
European market focus |
The product with NDC 27241-0041 competes primarily in North American and European biosimilar markets, where manufacturers are seeking to increase market share by offering lower-cost alternatives.
Regulatory and Market Dynamics
Patent Expiry and Market Entry
Humira’s main patents expired in the U.S. in 2023, opening opportunities for biosimilars. The biosimilar associated with NDC 27241-0041 likely launched shortly after, leveraging patent landscape changes.
Reimbursement Policies
Reimbursement policies favor biosimilars that have received approval from the FDA and EMA. Hospitals and payers prefer biosimilars due to lower costs, which influences market penetration.
Distribution Channels
Distribution includes hospital formulary adoption and specialty pharmacy networks. Competitive pricing and educational outreach significantly impact adoption rates.
Price Projections
Current Pricing Landscape
| Brand/Product |
Estimated Wholesale Acquisition Cost (WAC) |
Estimated Average Sales Price (ASP) |
Monthly Treatment Cost |
| Humira (reference) |
$5,800 per 40 mg pen |
$6,000 |
$6,000 |
| Biosimilar (NDC 27241-0041) |
$4,000 - $4,500 per 40 mg pen |
$4,200 - $4,700 |
$4,200 - $4,700 |
Biosimilar prices are generally 20-30% lower than the reference biologic. As biosimilar market share grows, prices tend to decrease further.
Projected Pricing Trends (Next 3-5 Years)
- Year 2023-2024: Biosimilar prices stabilize at 25-30% below the originator, with price erosion driven by increased competition.
- Year 2025-2027: Prices decline further by 10-15%, reaching approximately $3,500-$4,000 per 40 mg treatment course.
- Long-term outlook: Market saturation may lead to price stabilization or slight increase due to supply chain adjustments; however, intense competition limits significant upward movement.
Market Penetration and Revenue Outlook
By 2027, biosimilar adalimumab products, including the one associated with NDC 27241-0041, are projected to capture 50-60% of adalimumab prescriptions in North America, translating into revenue estimates of approximately $8-10 billion globally.
Key Drivers Affecting Price and Market Share
- Launch date and marketing strategy.
- Payer and hospital adoption rates.
- Patent litigations impacting exclusivity.
- Policy changes favoring biosimilars.
- Pricing strategies of competitor biosimilars.
Strategic Implications
- Companies must differentiate through cost leadership and educational efforts.
- Early market entry after patent expiry maximizes market share.
- Cost reductions will likely continue with scale; niche markets may command higher prices.
Key Takeaways
- NDC 27241-0041 relates to a biosimilar of adalimumab, with significant growth potential post-Humira patent expiration.
- The biosimilar market is highly price-sensitive; expect ongoing price erosion over the next 3-5 years.
- Revenue potential depends on market uptake, which is driven by pricing, formulary inclusion, and payer policies.
- Competition is intense, with multiple biosimilars launching in the U.S. and Europe.
- Long-term, biosimilar adalimumab could account for over half of adalimumab prescriptions, with total revenue approaching $10 billion globally.
FAQs
What is the primary market opportunity for biosimilar NDC 27241-0041?
The opportunity lies in replacing costly biologics post-patent expiration, capturing significant market share via aggressive pricing and payer negotiations.
How does regulatory approval impact the market penetration?
Full regulatory approval from major agencies (FDA, EMA) enhances confidence among healthcare providers and payers, accelerating adoption.
What factors most influence biosimilar pricing?
Competition intensity, manufacturing scale, patent litigation, and reimbursement policies are key factors.
When can manufacturers expect profitability from biosimilar NDC 27241-0041?
Profitability depends on launch timing, market share captured, and price erosion but generally occurs within 2-3 years if early entry and adoption are achieved.
How does biosimilar market competition affect future prices?
Increased competition tends to lower prices further, especially as additional biosimilars enter the market and consolidate share.
References
- IQVIA. (2022). Global biosimilar market report. IQVIA.
- U.S. Food and Drug Administration. (2022). Biosimilars: What You Need to Know. https://www.fda.gov/
- EvaluatePharma. (2023). Adalimumab Biosimilars Market Analysis. Evaluate Pharma.
- Centers for Medicare & Medicaid Services. (2022). Biosimilar reimbursement policies. CMS.
- European Medicines Agency. (2022). Guidelines on biosimilar approval. EMA.
Note: Data and projections are based on publicly available industry reports and market analyses as of 2023 and may fluctuate based on market dynamics, regulatory decisions, and competitive actions.
